De-escalating first-line treatment in stage IVB or recurrent cervical cancer: outcomes of immunotherapy alone and systemic review
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf096 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Oncologist, 2025. Verfasst von Akram Saad und 11 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Tel Aviv University, P.O.B 39040 Ramat Aviv, Tel Aviv 69978, Israel. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Immunotherapy, Neoplasm Recurrence, Local. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Parasol Foundation.
Abstract (Originalsprache)
Introduction
Chemo-immunotherapy (IO) is the preferred first-line treatment for stage IVB or recurrent cervical cancer. However, limited data exist on the efficacy and safety of using IO-alone as a de-escalation strategy. We report outcomes from a case series of selected patients treated with IO-alone and review the feasibility of de-escalating first-line treatment.
Methods
The authors conducted a literature review using Google Scholar and PubMed to identify reports using IO-alone as a de-escalation strategy across malignancies published between 1999 and December 2024 and also reviewed a cervical cancer database from a tertiary academic to identify patients with stage IVB or recurrent disease treated with IO-alone. The authors used the Kaplan-Meier method to estimate progression-free survival (PFS) and overall survival (OS).
Results
Among 582 patients treated between 2015 and 2021, 18 met the inclusion criteria. The median age was 43 years (range 28-84); 67% had squamous cell carcinoma, 11% adenocarcinoma, and 80% expressed PD-L1. CPS scores were <1 in 20%, 1--10 in 33%, and >10 in 47%. Most patients had oligo-metastatic disease (83%). Treatment with IO-alone began a median of 7 months after platinum-based chemotherapy. Indications included prior adjuvant (44%) or neoadjuvant (22%) chemotherapy, clinical trial participation (11%), or patient preference (22%). Median PFS and OS were 27 months and 82 months, respectively.
Conclusions
These findings support the need for clinical trials evaluating IO-alone as a first-line treatment option for de-escalation in stage IVB or recurrent cervical cancer. Biomarker development is needed to better identify candidates for personalized therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Tel Aviv University, P.O.B 39040 Ramat Aviv, Tel Aviv 69978, Israel.
- Sheba Cancer Center and Institute of Oncology, Tel-Hashomer, Derech Sheba 2, Ramat Gan, Israel.
- The Royal Marsden, Department of Clinical Oncology, 203 Fulham Rd., London SW3 6JJ, United Kingdom.
- Gynecologic Oncology, Sheba Medical Center, Tel-Hashomer, Derech Sheba 2, Ramat Gan, Israel.
- Rappaport Faculty of Medicine, Technion Israel Institute of Technology, 1 Efron St. Bat Galim, Haifa 3525433, Israel.
- Tel Aviv Sourasky Medical Center, Department of Radiation Oncology, Weizmann St 6, Tel Aviv-Yafo, Israel.
ORCID-Profile: Keren Levanon, Ronza Atamneh, Samantha Breslauer, Shira Peleg Hasson
Förderung
- Parasol Foundation
Zitieren
APA
Saad, A., Taylor, A., Felder, S., Helpman, L., Bauer, S., Shapira, R., Levanon, K., Korach, J., Atamneh, R., Breslauer, S., Goldstein, J., & Peleg Hasson, S. (2025). De-escalating first-line treatment in stage IVB or recurrent cervical cancer: outcomes of immunotherapy alone and systemic review. The Oncologist. https://doi.org/10.1093/oncolo/oyaf096
Vancouver
Saad A, Taylor A, Felder S, Helpman L, Bauer S, Shapira R, et al. De-escalating first-line treatment in stage IVB or recurrent cervical cancer: outcomes of immunotherapy alone and systemic review. The Oncologist. 2025. doi:10.1093/oncolo/oyaf096
BibTeX
@article{Saad2025,
author = {Saad, Akram and Taylor, Alexandra and Felder, Shira and Helpman, Limor and Bauer, Smadar and Shapira, Ronnie and Levanon, Keren and Korach, Jacob and Atamneh, Ronza and Breslauer, Samantha and Goldstein, Jeffrey and Peleg Hasson, Shira},
title = {De-escalating first-line treatment in stage IVB or recurrent cervical cancer: outcomes of immunotherapy alone and systemic review},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf096}
}
EUVIMED